Working Towards a Translational Programme in RAS Targeting
Tuesday 25 February: 14.00-16.30
In 2019, the first reports of clinical efficacy using direct inhibitors of KRAS G12C were released, already showing great promise for the future implementation of these drugs in the cancer clinic. In parallel, current clinical trial evidence suggests that lung cancers driven by KRAS mutation are also vulnerable to treatment with immune checkpoint inhibitors. The aim of this workshop is to share our experience of pursuing a RAS translational programme in the clinic across two Cancer Research UK institutes.
The first part of the workshop will examine what constitutes a successful biomarker for clinical roll-out, drawing parallels with the progress achieved in other molecular sub-sets of cancer where established treatment approaches are still improving. The second part of the workshop will explore what delegates consider to be the optimal cell line and animal models for study of the MAP kinase pathway and its immunotherapeutic vulnerabilities.
Topics to be covered:
- How are biomarkers successfully translated for the clinical application of small molecules and immunotherapy?
- What lessons can be taken from other examples of successful small molecule drug targeting in cancer, such as EGFR mutation or ALK re-arrangement?
- How is next generation sequencing being implemented in hospitals?
- What are the optimal tissue culture models for studying RAS-driven cancer?
- What are the optimal animal models for studying RAS-driven cancer?
Senior Group Leader & Professor of Cell Biology, Cancer Research UK Manchester Institute - The University of ManchesterDr. Angeliki Malliri completed my bachelors degree in Biology in the University of Patras, Greece and obtained her PhD from the University of Crete, Greece. She worked as a postdoctoral scientist in the Beatson Institute for Cancer Research, Glasgow, UK read more
Clinical Senior Lecturer, The University of Manchester; Medical Oncology Consultant - The Christie NHS Foundation TrustDr. Colin Lindsay is a Clinical Senior Lecturer in medical oncology, dividing his time 50/50 between research and the clinic. Originally he trained at the CRUK Beatson Institute and Cancer Centre in Glasgow, where he completed a PhD studying genetically-modified read more
Senior Laboratory Research Scientist - Francis Crick InstituteDr. Miriam Molina-Arcas obtained her PhD in Biomedicine at the University of Barcelona (Spain) in 2005. After a first postdoctoral project at the University of Barcelona, in 2008 she joined 23/01/2020Dr. Julian Downward’s laboratory at the London Research Institute and read more